Blog

Analysis of retatrutide news, regulatory timing and evidence. Every claim is traced to a source, and these posts say so when they have not been individually medically reviewed.

1. September 25, 2026

   Retatrutide Safety Data: What the Trials Can and Cannot Tell You

   What the retatrutide safety data covers: how many people, how long, who was enrolled, and what trials of this size cannot show about rare or long-term risks.

2. September 25, 2026

   Retatrutide FDA Approval Timeline: What Lilly Has Said and What Happens Next

   Lilly plans to file for FDA approval of retatrutide in Q1 2027. What a filing starts, how long FDA review takes and why no approval date exists yet.

3. September 25, 2026

   How to Read Retatrutide News: Trial Phases, Topline Results and What Counts as Evidence

   A plain guide to retatrutide headlines: what each trial phase shows, how company announcements differ from peer-reviewed papers, and five questions to ask of any claim.

4. September 25, 2026

   Can You Buy Retatrutide? What FDA Says About Unapproved GLP-1 Products

   Retatrutide has no FDA-approved product. What FDA has said about unapproved GLP-1 drugs and research-use labels, the risks it names, and safer next steps.